Purpose of Review Molecular imaging of cardiovascular disease is a powerful clinical and experimental approach that can inform our understanding of atherosclerosis biology. Complementing cross-sectional imaging techniques that provide detailed anatomical information, molecular imaging can further detect important biological changes occurring within atheroma and refine the prediction of vascular complications. Recent Findings Molecular imaging of atherosclerosis can illuminate underlying pathophysiology and serve as a surrogate endpoint in clinical trials of new drugs. Summary This review showcases promising molecular approaches for imaging atherosclerosis, with a focus on positron emission tomography (PET), magnetic resonance imaging (MRI), and intravascular near-infrared fluorescence (NIRF) imaging methods that are in the clinic or close-to-clinical usage.
Introduction
Atherosclerosis-induced cardiovascular disease is a major global health problem and a major cause of death in every region of the world [1] . In clinical practice, anatomical imaging modalities such as computed tomography (CT), ultrasound (US), and magnetic resonance imaging (MRI) are essential to delineate vascular anatomy and diagnose atherosclerosis stenosis severity, but do not routinely provide information about underlying pathophysiological processes driving the disease and its consequences. Advances in molecular atherosclerosis imaging research provide opportunities to explore pathological mechanisms occurring at the cellular level and within the vessel wall. When applied to studying atherosclerosis, nuclear imaging with positron emission tomography (PET) has the potential to detect early vascular changes, prior to the onset of clinical symptoms, or even before angiographically detectable luminal stenosis. In addition, cross-sectional multi-modal imaging using combined PET/CT or PET/MRI systems offers great potential to incorporate anatomical, functional, and molecular datasets. Furthermore, catheter-based near-infrared fluorescence imaging (NIRF) molecular imaging has enabled high-resolution insights into atherosclerosis progression, stent restenosis, and stent thrombosis. This review will highlight promising novel approaches, with a focus on recent advances in the literature.
Among the positron-emitting isotopes which can be produced, the most commonly used in PET are those having a short halflife and which are present naturally in many biological compounds, such as 11 C, 18 F, 15 O, and 13 
N.
The most common radiopharmaceutical in PET is 2-[ 18 F] fluoro-2-deoxy-D-glucose ( 18 F-FDG), a compound which was first administered to patients in the late 1970s and now utilized in over 90% of clinical PET scans. It is an analog of glucose allowing quantitation of glucose metabolism, and it is most commonly used for cancer detection, staging, and monitoring, being considered the gold standard for the in vivo assessment of many tumor types.
When a positron is emitted from the nucleus, it travels a short distance (typically 1-2 mm) until it collides with an electron. The positron-electron collision results in an annihilation event, which produces radiation in the form of two photons, each with an energy of 511 keV, emitted in opposed directions. PET detection systems are poised to identify the coincidentally emitted photon pairs and reconstructs the line from which they originated (hence enabling quantification of tissue activity). A common measure of PET tracer uptake is the standardized uptake value (SUV). The SUV is a semiquantitative measure, subsequently adjusted for injected tracer dose and body weight. When SUV is corrected for blood pool activity (the circulating level of tracer in the venous system), the target-to-background ratio (TBR) is derived. Ongoing work is establishing the relative merits of SUV and TBR measures in PET characterization of atherosclerosis [2] .
FDG-PET Molecular Imaging of Inflammation in Atherosclerosis
Fluorodeoxyglucose ( 18 F-FDG) is a radiolabeled glucose analog that is taken up by all glucose-metabolizing cells. Once internalized, it becomes metabolically trapped and accumulates in direct proportion to the tissue rate of glycolysis. By exploiting the glucose-dependent metabolism of macrophages in atherosclerosis, FDG PET can illuminate macrophage burden in vivo [3] [4] [5] .
Initial Clinical Studies Rudd et al. performed the first prospective validation study of using FDG to detect and quantify atheroma inflammation [5] . The authors observed significantly higher FDG tracer uptake within symptomatic carotid plaques when compared to the contralateral asymptomatic carotid artery. Histological validation was performed in a second key study, in which PET imaging was performed on individuals scheduled for endarterectomy, and FDG uptake quantified from those images was later compared to detailed immunohistochemical analysis of the excised plaque specimens [6] . Quantitative analysis subsequently revealed that the intensity of the FDG uptake correlated well with the macrophage content of plaque specimens (r = 0.70, p < 0.001) (Fig. 1) . These pivotal studies established the utility of FDG to assess plaque inflammation, with subsequent applications to understanding atherosclerosis pathophysiology and to assessing pharmacotherapies. Fig. 1 FDG uptake in carotid plaques of patients. Axial images of both CT and PET data from a patient with low (PET a) and high (PET b) FDG uptake in the region of the internal carotid artery (arrows). FDG was associated with histological plaque macrophages, a key inflammatory cell driver of plaque complications. Reproduced by permission from Ref. [6] Relationship of FDG Uptake to Other Plaque Constituents Carotid artery FDG uptake has also been shown to relate to the extent of neovascularization, a marker of plaque hypoxiaimplicated in pathogenesis of the unstable atherosclerotic plaque [7] . In a recent study by Taqueti et al., patients undergoing carotid endarterectomy underwent 18 F-FDG PET/CT imaging prior to surgery. The endarterectomy specimens were then analyzed for macrophage content (CD68), activated inflammatory cells (MHC class II), and microvessels (CD31). Increased FDG uptake was observed in inflamed plaque regions as demonstrated in earlier studies, but the authors also observed increased FDG uptake in areas of increased microvascular permeability, perfusion, and microvascularizationpossibly implicating positive uptake in areas that are linked to unstable plaque. Pathophysiologically, the presence of neovasculature may facilitate delivery of FDG to metabolically active cells.
FDG uptake in atherosclerotic specimens has also been linked to plaque hypoxia [4] . A recent study provided insights into the relationship between hypoxia and macrophage content and function. That study demonstrated that hypoxia triggered increased pro-inflammatory activity by macrophages, via a HIF-1 alpha-dependent mechanism. Furthermore, the study showed that glycolytic flux remained closely related monocyte pro-inflammatory actions (e.g., TNF alpha production), regardless of whether or not hypoxia was present [8•] . Hence, the amount of FDG that accumulates within macrophages is influenced not only by the number of inflammatory cells but also their pro-inflammatory phenotype, which can be impacted by hypoxia as well as other factors.
Arterial FDG Signal as a Predictor of Atherosclerotic Disease Progression and Clinical Events Moustafa et al. examined the role of 18 F-FDG PET/CT in patients with symptomatic carotid disease [9] . They identified a positive correlation between microembolic signals identified from transcranial Doppler and carotid FDG uptake on PET/CT. Notably, the percent luminal stenosis did not differentiate plaques that produced microemboli [10] . Similarly, cross-sectional studies revealed that both aortic and coronary arterial FDG uptake increase after myocardial infarction [11] .
The arterial FDG signal can also predict the progression of underlying atheroma. Abdelbaky et al. observed that atheromatous plaques with high FDG uptake subsequently undergo more rapid atherosclerotic progression (measured as incident arterial calcification) compared to arterial locations with lower amounts of FDG uptake [12] . Another study demonstrated that early changes in arterial FDG uptake predict later changes in plaque progression (plaque thickness, by MRI) [13] .
Moreover, the arterial FDG signal has been repeatedly shown to be an independent predictor of future atherothrombotic disease events. Rominger et al. first showed, in a population of individuals with oncologic diagnoses, that the arterial FDG signal predicts subsequent CVD events [14] . Extending those findings, Figueroa et al. studied individuals without active cancer and found that the arterial FDG signal independently predicted CVD events beyond coronary artery calcium measures or clinical risk scores (such as the Framingham Risk Score) [15] (Fig. 2) . Small prospective studies have demonstrated a similar relationship between arterial FDG uptake and subsequent CVD [16] .
FDG-PET Assessment of Anti-Atherosclerosis Pharmacotherapeutics Given that the FDG signal is reproducible [17] and that its modulation predicts atherosclerotic disease progression [13] , it is ripe for use as a biomarker to examine novel therapies. Indeed, several studies have assessed the impact of anti-inflammatory pharmacotherapy on the FDG signal. A question of substantial importance is whether the directional changes seen in the PET signal relate to directional changes seen in clinical endpoint evaluations in the context of pharmacotherapy. To date, insights are emerging from trials of five therapeutic compound classes for which there are both FDG-PET as well as clinical endpoint trial data.
The first such drug class is statins. Several groups have shown that statins are associated with reduction in arterial FDG uptake [18, 19] , findings that are undoubtedly in line with reductions in CVD events imparted by statins [20] . Interestingly, the magnitude of signal reduction might also be important. High-dose statins have a 2-fold greater impact on the arterial signal compared to low-dose statins [19] , a finding that is concordant with the observation that highdose statins reduce CVD events roughly twice as well as low-dose statins. Similarly, the thiazolidinedione, pioglitazone, was found to significantly reduce arterial FDG uptake in diabetic patients [21] . Likewise, TZDs have been shown to reduce CVD events in this population [22] .
On the other hand, a lack of change in the arterial FDG signal may forecast a lack of therapeutic efficacy. Fayad et al. [23••] demonstrated that dalcetrapib (a modulator of cholesteryl ester transfer protein activity) did not reduce any of the pre-specified FDG-PET measures. Likewise, dalcetrapib failed to improve clinical outcomes in a large outcomes trial [24] . More recently, a selective inhibitor of lipoprotein phospholipase A2 was assessed using arterial FDG-PET imaging and was found to be ineffective at reducing the FDG signal [25] . Concordantly, Lp-PLA2 inhibitors have subsequently been found to be ineffective in reducing CVD events [26, 27] . Most recently, the results of both imaging and clinical outcomes trials of drugs targeting p38 MAP Kinase have been reported. One PET study reported no change in the signal, when the pre-defined endpoints were used, but identified a possible reduction in the signal using an exploratory endpoint [28] . However, a subsequent study found no reduction in the PET signal using any of the measured FDG endpoints [29] . A subsequent trial of p38 MAPK antagonism on CVD events subsequently found no benefit [30] . Thus, for all five drug classes for which there are both imaging and clinical endpoint trial data, there has been concordance between the pre-specified imaging results and clinical endpoint results. Accordingly, arterial FDG-PET imaging, when used in phase II trials, may be used to identify drugs with greater likelihood for success in phase III studies.
FDG-PET Molecular Imaging of Inflammation in Abdominal Aortic Aneurysm (AAA)
Inflammation is a key driver of AAA expansion and rupture, and the ability to assess AAA inflammation could improve risk stratification and motivate specific anti-inflammatory therapies. A small number of studies have explored the utility of FDG-PET/CT imaging to characterize AAA. One pilot study of 26 patients with AAA suggested a possible positive correlation between 18 F-FDG uptake and aneurysmal growth rate and rupture [31] . In contrast, a relatively brief longitudinal observational study [32] of 39 patients with small-to-medium size AAA failed to replicate those findings (in fact there was in inverse association between tracer uptake change in AAA diameter). However, it should be noted that very few subjects experienced progression of AAA diameter in that study, likely due to the relatively short follow-up period (of only 9 months). Since AAA diameters tend to enlarge at a rate of 2-3 mm per year [33] , a 9-month follow-up period employed in that study may have been insufficient to robustly test the hypothesis. Accordingly, the relationship between FDG uptake in AAA and subsequent AAA behavior remains unclear and requires further investigation.
FDG-PET Molecular Imaging of Inflammation in Peripheral Atherosclerosis
Relatively few molecular imaging studies have focused attention on the lower limb arterial tree. This may be due to the fact that those vessels tend to be relatively small, and that atherosclerotic inflammation may play a less important role in the lower limb atherosclerosis. The available data are derived from studies using multiple different tracers assessing perfu 68 Ga-NOTA-RGD, 64 Cu-DOTA-CANF-comb, 64 Cu-DOTA-VEGF), or atherosclerosis (including 18 F-FDG, 18 F-sodium fluoride, 11 C-acetate, 64 Cu-DOTA-CANF) [34, 35] . Studies have also compared FDG uptake in peripheral vessels using PET/CT and PET/MRI in carotid and peripheral vessels [36] . Silvera et al. demonstrated that both imaging modalities accurately identified areas of lipid-rich plaques more often than collagen-rich or calcified plaques.
PET Molecular Imaging of Plaque Osteogenic Activity (Active Calcification)
Cardiovascular calcification is associated with an increased risk of vascular events [37] . Specifically, coronary artery calcification score (CAC) is now widely used to refine the Fig. 2 Arterial FDG uptake associates with the risk of subsequent CVD events. a A study of 519 individuals without active cancer or pre-existing cardiovascular disease found that those with high aortic FDG uptake (the highest tertile of activity) were
Reproduced by permission from Ref. [15] prediction of future coronary artery events including myocardial infarction and cardiac death [38] . Although vascular wall calcification seen on CT is considered a powerful surrogate risk factor for poor cardiovascular outcome, it represents the end stage of the overall calcification process [39] . New approaches using PET/CT imaging to assess the active calcification stage might improve risk prediction further and offer an opportunity to initiate directed anti-atheroma therapy earlier. on the surface of the hydroxyapatite matrix to form fluoroapatite [40] . As such, its primary clinical application has been in the evaluation of primary and metastatic bone tumors [41] . A major advantage of 18 F-NaF is the lack of myocardial background compared to FDG, allowing high conspicuity of 18 F-NaF+ coronary lesions. More recent interest has focused on its role in identifying areas of active microcalcification within the cardiovascular system and specifically in atherosclerosis where it is believed that microcalcification may play a role in plaque rupture through both mechanical and inflammatory effects.
Initial Clinical Studies Prior studies established a strong link between chronic inflammation and the subsequent development of soft tissue calcification in atherosclerosis [42] . Clinically, Derlin et al. [43] first described correlations and distinct differences across plaques while imaging with FDG and 18 F-NaF, and found overlap of the two tracers in only 6.5% of plaques of various arterial beds, suggesting each tracer reports on different plaque pathological processes. Abdelbaky et al. evaluated 137 patients by determining the degree of aortic inflammation using 18 F-FDG PET/CT scanning and found that higher levels of inflammation were significantly associated with subsequent CT calcification over a 5-year period [44] .
Derlin et al. further demonstrated the potential to image to early-stage, or "active," microcalcification in atherogenesis using 18 F-NaF in human carotid plaques [45] . In a key study, this work was extended into the human coronary artery domain by Dweck and Newby [46] , who demonstrated outstanding signal-to-noise ratio of NaF uptake in coronary plaques (Fig. 3) . In a landmark study, Dweck and colleagues further demonstrated the value of 18 F-NaF to prospectively demonstrate that high 18 F-NaF uptake was associated with high-risk, often ruptured carotid and coronary lesions, with histological evidence of active calcification, macrophages, necrosis, and apoptosis [47••] . A recent retrospective study by Fiz et al. [48] further assessed the correlation between calcification density (as assessed by CT, in Hounsfield units) and 18 F-NaF uptake within the infrarenal aorta of oncology patients. There was a significant inverse correlation between 18 F-NaF uptake and macrocalcification, supporting the concept that 18 F-NaF may act as a valid marker of calcium deposition primarily in the early stages of plaque formation.
Recently, detailed mechanistic studies of NaF tracer selectivity, specificity, and pharmacodynamic behavior have been performed in vitro and in human carotid plaques [49•] . Irkle et al. demonstrated that 18 F-NaF adsorbs to calcified deposits within plaque and is highly selective and specific, and further non-invasively detects areas of microcalcification that are associated with active unstable atherosclerosis. To this effect, 18 F-NaF co-localized to areas of nascent calcification and could mark a novel non-invasive biomarker of the high-risk pathology. Furthermore, the study has suggested that adsorption is dependent primarily on surface area, consistent with the notion that the complex surface of microcalcifications allows more binding.
18
F-NaF PET and Outcome Studies A molecular imaging modality that identifies early active microcalcification and allied inflammatory processes within atherosclerotic plaques could allow for a refined understanding of plaque vulnerability and prediction of lesion-specific or artery-specific hard events such as myocardial infarction, stroke, and sudden death. In the next several years, outcome studies are anticipated, including a multicenter observational study of 18 F-NaF PET as a marker of coronary plaque vulnerability to detect culprit and non-culprit unstable coronary plaques in patients with recent myocardial infarction (NCT02278211 at clinicaltrials.gov). The investigators plan to follow these patients to determine the prognostic significance of coronary 18 F-NaF uptake. A key question is whether 18 F-NaF will offer significant predictive ability beyond the traditional calcium marker of coronary artery calcium (CAC) scoring, which has an established role in risk prediction in the primary prevention CAD population.
Alternate PET Tracers
An important limitation of coronary FDG imaging is that the coronary plaque signal may be overwhelmed by high myocardial uptake. Therefore, the search for additional PET tracers that assess vascular inflammation remains important. It has been demonstrated that in retrospective studies, there is positive uptake of this tracer in coronary arteries [50] as well as in aorta, iliac, and carotid vessels [51] . 68 Ga-DOTATATE offers a coronary imaging advantage as there is minimal uptake in the myocardium, in distinction to FDG. Positive 64 Cu-DOTATATE uptake in human carotid plaques further correlates with cellular markers of inflammation (CD68 and CD163) [52] . Furthermore, in a comparison with a similar somatostatin analog tracer, 68 Ga-DOTATOC, 68 Ga-DOTATATE correlated better with inflamed arteries alongside traditional cardiovascular risk factors-suggesting a potential role in atherosclerotic disease assessment [53] . Prospective validation is, however, warranted.
11
C-PK11195 targets the translocator protein (TSPO) on the macrophage surface. Its use in vascular imaging is challenging due to the shorter half-life of carbon 11 (20 min), but it has been utilized as a marker of plaque inflammation, particularly in the carotid circulation [54, 55] . An advantage of this tracer is the significant correlation between 11 C-PK11195 uptake ratio and autoradiographic measurement of translocator protein binding sites [55] . 18 F-Fluorodeoxymannose (FDM) is an isomer of glucose and has been postulated to be expressed on the M2 (more reparative) subtype of macrophages. Its use in research has been limited to preclinical animal work [56] , yet further work may be published once radiolabeling becomes simpler. Nonetheless, Tahara et al. proposed that as supported by in vitro investigations, FDM had a 35% higher uptake compared to FDG based on lower inhibition of hexokinase activity, suggesting it may be more specific for areas of acute inflammation. Further investigation, including feasibility of clinical FDM imaging, is required to understand if FDM can provide additional or complementary clinical value in comparison to FDG in risk prediction.
Ultrasmall Superparamagnetic Iron Oxide Nanoparticle-Enhanced MRI Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles are a well-established class of dextran-based MRI agents F-NaF tracer uptake in culprit lesion with f associated in situ thrombus in the proximal right coronary artery. Reproduced by permission from Ref. [45] that report on phagocytic cellular activity. Several preparations have been clinically tested and one preparation, feurmoxytol, is FDA approved as replacement therapy for iron-deficient chronic kidney disease patients. With regards to atherosclerosis imaging, intravenously administered longcirculating UPSIO nanoparticles are eventually taken up by macrophages and thus allow visualization of macrophageladen plaque. Their properties allow direct imaging on T2-weighted MRI sequences, where they induce a loss of MR signal.
USPIO-enhanced molecular MRI can assess inflammatory plaque burden in aortic aneurysms, carotid artery disease, myocardial infarction, and response to pharmacotherapy. Kooi et al. [57] first demonstrated successful histologically confirmed USPIO (ferumoxtran) MRI of macrophage content in carotid plaque rupture-prone zones of patients undergoing carotid endarterectomy (validated with histology and electron microscopy). In a unique clinical trial, the ATHEROMA Study [58] provided new insights into the comparative of efficacy of low-potency versus high-potency statin therapy in attenuating plaque macrophages in patients. The authors evaluated the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin therapy on carotid plaque inflammation in 47 patients and demonstrated a significant reduction in UPSIOdefined inflammation in patients receiving high-dose statin therapy (p = 0.0003). Currently, long-circulating USPIOs such as ferumoxtran are not routinely clinically available, which has limited USPIO MRI atherosclerosis imaging studies in recent years.
However, new data has emerged by repurposing FDAapproved ferumoxytol for molecular MRI. One study [59] investigated UPSIO MRI imaging in patients suffering a myocardial infarction and demonstrate areas of increased USPIO uptake in acute infarction as well as remote myocardium (n = 16; p < 0.001). Further work is required to assess its range of applications in the acute setting. In addition, in comparative studies with 18 F-FDG PET, USPIO ferumoxytol MRI identified vascular inflammation reliably in abdominal aortic aneurysms, yet subtle differences compared to FDG suggest that inflammatory cell phagocytosis and glycolysis may not exactly coincide [60] . As ferumoxytol is a weaker T2 MRI contrast agent than ferumoxtran, it is not clear that ferumoxytol is strong enough to allow assessment of inflammation in smaller targets than the heart or aorta, such as carotid or coronary atheroma.
High-Resolution Molecular Imaging Via Intravascular Near-Infrared Fluorescence Imaging
Optical imaging using near-infrared fluorescence (NIRF) light is an emerging imaging technique delivering high sensitivity and the ability to be employed to image a wide range of molecular entities in vivo, via a versatile fluorescent probe design [61] [62] [63] . The use of NIR wavelengths allows deeper photon penetration into tissue and reduced tissue autofluorescence, resulting in higher sensitivity to detect exogenous NIR fluorophores (molecular imaging agents). Greater depth can be probed in the far-red or near-infrared spectral region as the absorption is as at least one order of magnitude lower than in the visible range. NIR light (650-900 nm wavelength) can penetrate several centimeters into tissue. Furthermore, as optical imaging is routine in the cardiac catheterization laboratory (via intravascular optical coherence tomography), intravascular NIRF offers a promising translational approach into clinical coronary arterial imaging. Excitingly, the first human intravascular NIRF imaging study was recently performed and demonstrated the ability to sensitively detect NIR autofluorescence in human coronary arteries [64•] . This study paves the way forward for targeted intravascular NIRF molecular imaging studies in coronary patients.
Given the favorable high sensitivity in the NIR window, NIRF imaging can further enable signal detection through blood. The first real-time catheter molecular sensing probe was first described by Jaffer et al. [65] , who detected in vivo inflammatory cysteine protease activity in experimental atheroma of human-sized arteries. The first rotational, automated 2D imaging catheter was engineered by Jaffer et al. [66] and intra-arterial imaging of stented rabbit aortas and coronary bare-metal stents demonstrated excellent nanomolar sensitivity to fluorophores to image plaque and stent injury-induced arterial inflammation. Further research into this novel imaging approach will also target key molecules in atherosclerosis (i.e., oxidised low density lipoprotein (OxLDL), acetylated low density lipoprotein (LDL), matrix metalloproteinases (MMPs)). Recently for example, Khamis et al. [67] developed an antibody-based NIRF approach for targeting OxLDL in vivo-providing new potential avenues for exploring molecular compositions of atheroma longitudinally with intravascular NIRF imaging. In addition, FDA-approved indocyanine green is a promising translational NIR fluorophore for plaque imaging [68] and has recently been shown to report on impaired endothelial barrier function in human plaques [69•] .
One limitation to standalone NIRF imaging is the lack of co-registration (analogous to PET imaging without CT/MR anatomical information). One potential exciting approach is dual-modality NIRF-optical coherence tomography (OCT). This concept has been translated into an intravascular imaging system [70•] (Fig. 4) and revealed the ability to successfully co-localize microstructural and biological imaging data. Characterization in vivo of inflammatory cells using OCT can quantify molecular expression and activity using cathepsin protease-activated NIR molecular beacons. Furthermore, stent-induced injury (fibrin deposition in restenosis injury, platelet deposition, and inflammatory endothelial infiltration) can be quantified and investigated using this single pullback technology [71] . Attesting to the translational potential of NIRF-OCT, an intravascular NIRF-OCT system reporting on NIR autofluorescence has been recently performed in the coronary arteries of patients [64•] . Further research into its clinical implications and translation is required-yet the highresolution information that such multi-modality imaging offers has the potential to transform coronary arterial molecular imaging of atherosclerosis.
Conclusions and Future Directions
Current risk stratifications in a number of vascular conditions are based primarily on anatomical data such as stenosis or calcium score. The advent of new molecular imaging techniques, including PET/CT and intravascular high-resolution NIRF-OCT, could enhance the identification of high-risk plaques, arteries, and patients harboring plaque inflammation or other pathobiology. These technologies, in particular FDG PET, have made significant clinical inroads into assessing atheroma pharmacotherapeutic efficacy in phase II clinical trials. Furthermore, development of novel tracers will enhance in vivo assessment of key pathobiological processes including inflammation, hypoxia, and neoangiogenesis. The overarching question is whether such imaging techniques will improve our understanding of human plaque biology, and ultimately the risk of plaque complication and restenosis, to identify better those patients where such vascular events can be preempted utilizing tailored systemic and/or local therapies. Given the ongoing translation of new imaging agents and new imaging devices, the future for atherosclerosis molecular imaging appears bright.
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